Axelia Oncology

Brandon Capital's $60m taypayer-funded biotech bets

Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.

Also australiatimes.com

Grit, strategy, and adaptability: the sportsmanship of biotech investing

A profile of Brandon Capital partner Chris Smith, tracing his path from immunology research and a Cambridge postdoc into biotech investing, with resilience lessons drawn from equestrian sport and companies Aravax and ENA Respiratory.

Australia’s first national biotech incubator announces round one funding to support life science breakthroughs

Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.

Australia's first national biotech incubator announces round one funding to support life science breakthroughs

The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.